Evidence map›Paper›PMID 42199196›Full record

ArticleIranian journal of pathology2026

Circulating HBcrAg, miRNA-122, and M2BPGi as Predictive Biomarkers for Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Case-Control Study.

Amgad Ahmed Ezzat Othman, Mohamed S Hemeda, Khaled Mohamed Hassanein Mohamed, Mohammed Saad Ahmed, Ayman S Yassin, Mohamed Nabil Mohamed, Abd Elmoaty Arafat Abd Elmoaty, Mahmoud M Khafagi, Mohammed Mostafa Mohammed Abdo, Mohamed Abdel Basit Ibrahim Mohamed

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Iranian journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Amgad Ahmed Ezzat OthmanDepartment of Medical Microbiology and Immunology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Mohamed S HemedaDepartment of Forensic Medicine and Clinical Toxicology, Faculty of Medicine, Port Said University, Port Said, Egypt.
Khaled Mohamed Hassanein MohamedDepartment of Medical Microbiology and Immunology, Faculty of Medicine, Assiut University, Assiut, Egypt.
Mohammed Saad AhmedDepartment of Medical Microbiology and Immunology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Ayman S YassinDepartment of Medical Microbiology and Immunology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Mohamed Nabil MohamedDepartment of Medical Microbiology and Immunology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Abd Elmoaty Arafat Abd ElmoatyHepatology and Infectious Diseases Department, Faculty of Medicine, Al-Azhar University, Assiut, Egypt.
Mahmoud M KhafagiHepatology and Infectious Diseases Department, Faculty of Medicine, Al-Azhar University, Assiut, Egypt.
Mohammed Mostafa Mohammed AbdoDepartment of Medical Microbiology and Immunology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Mohamed Abdel Basit Ibrahim MohamedDepartment of Medical Microbiology and Immunology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

miRNA-122, HBcrAg, M2BPGi, Hepatocellular carcinoma, Chronic hepatitis B, Forensic biomarkers, Toxicological relevance. Background & Objective: Hepatitis B Virus (HBV) infection has highly negative consequences for the global population, with chronic hepatitis B (CHB) infection and the resulting hepatocellular carcinoma (HCC) representing one of the most concerning long-term outcomes. This study focuses on the use of several biomarkers (miRNA-122, HBcrAg, and M2BPGi) in liquid biopsies to evaluate their efficacy in detecting early-stage HCC and assessing risk in patients with CHB. Methods: This study included 90 participants. Of these participants, 30 had chronic hepatitis B (CHB), 30 had hepatocellular carcinoma with HBV (HCC), and 30 were healthy controls. Serum miRNA-122 was quantified with real-time PCR, and HBcrAg and M2BPGi were measured using ELISA. Results: MiRNA-122 had an AUC of 0.801 and a sensitivity of 85.2%, indicating the highest diagnostic performance among the studies evaluated. M2BPGi demonstrated strong performance, with an AUC of 0.84. By contrast, HBcrAg had a very weak discriminative value. These previously stated biomarkers can improve the peripheral non-invasive screening. Conclusion: In this initial cohort study, circulating miRNA-122 and M2BPGi demonstrate an unsuspected capacity to predict HCC differentiation in CHB patients. However, these are preliminary and have yet to be tested for robustness across multicenter studies with appropriately estimated sample sizes.

Identifiers

PMID42199196
PMCPMC13200588

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.